Preqlinic Limited Secures £75k Funding Round at £2.3m Valuation to Streamline Preclinical Biotech Processes

Preqlinic Limited, a London-based company leveraging AI-enabled technology and human expertise to streamline the preclinical process for biotech firms, has successfully raised £75k in a new funding round. The investment, filed on 2026-04-29 with an allotment date of 2026-04-20, values the company at an estimated £2.3m post-money.

Founded on 2025-10-31, Preqlinic addresses a critical challenge in early-stage biotech programmes: the loss of time, capital, and credibility due to fragmented preclinical planning and regulatory execution. The company's proprietary solution provides structured, regulator-informed preclinical blueprints and a knowledge base, empowering scientists and regulatory teams to plan and execute with greater speed and confidence. This approach aims to help biotech firms and their investors accelerate treatments to patients, reduce waste, and optimise capital expenditure. Preqlinic currently operates with a team of three employees and is headquartered in London. Further financial metrics such as revenue or profit/loss figures were not disclosed. The company's website is http://www.preqlinic.com.

This latest £75k funding injection marks a significant step for Preqlinic, building on two previous early-stage rounds. The company previously secured £10k on 2025-12-08 at a valuation of £860k, followed by another £20k on 2026-01-13 at an £880k valuation. The current round's estimated post-money valuation of £2.3m represents a substantial increase, reflecting growing confidence in Preqlinic's innovative approach and market potential.

The funding round for Preqlinic comes amidst a dynamic period for the UK's biotechnology and health tech sectors. While 2025 presented a challenging financing environment for UK biotech, with equity financing reaching £1.9 billion, a 13.2% decrease in venture capital year-on-year, and investors becoming highly selective, the first quarter of 2026 has shown signs of recovery. Total equity financing in the UK biotech sector reached £552 million between January and March 2026, an increase from £466 million in Q4 2025. Venture capital investment, a primary driver, rose 17% quarter-on-quarter to £516 million, indicating a growth in investor confidence.

Notably, Q1 2026 saw a broader distribution of investment across more companies and stages, with deal activity increasing significantly to 25 venture capital transactions, a 67% year-on-year rise. The UK also secured 57% of all European biotech venture capital during this quarter, reinforcing its position as a leading destination for life sciences investment. Early-stage activity, such as Preqlinic's recent raise, has also strengthened in volume terms, reinforcing the depth of the UK's innovation pipeline.

For the broader health tech sector, Q1 2026 saw £177 million in equity funding across 34 rounds. Despite a reported drop in overall health tech funding compared to Q1 2025, the outlook for 2026 suggests a sustained recovery in venture capital investment, particularly for novel science and deep tech at early stages where valuations are considered reasonable. The UK government's NHS 10-Year Health Plan, published in July 2025, also creates significant growth opportunities for UK Health Tech, with a focus on major investment in AI, data, and automation. This strategic alignment with AI-driven solutions, such as those offered by Preqlinic, positions companies in this niche for continued interest and investment.